THE LYMPHATIC VASCULAR SYSTEM transports fluids, macromolecules, and immune cells from peripheral tissues through the lymph nodes on to the large veins in the neck. Transportation of lymph from organs and tissues to the blood vascular system normally occurs against a net hydrostatic pressure gradient and depends on a number of extrinsic and intrinsic factors to generate and maintain lymph flow (37) . Active lymph transport arises from the rhythmic phasic contractions of lymphatic muscle cells invested in the walls of collecting and transport lymphatics. These lymphatics possess a system of one-way valves that maintain net unidirectional flow and divide the lymphatics into a series of individual pumping chambers, called lymphangions (27) .
Lymphatic muscle has traditionally been considered a specialized type of vascular smooth muscle. Like vascular smooth muscle, the contractile activity of lymphatic muscle is modulated by various vasoactive (1, 2, 34, 55) and mechanical factors (3, 15, 26, 39, 54) . Unlike most blood vascular smooth muscle, lymphatic muscle exhibits a rapid, phasic form of contractile activity that drives the intrinsic lymphatic pumping in addition to the slower, tonic form of contractions seen in blood vascular muscle. The primary determinant of vascular smooth muscle contraction is the intracellular Ca 2ϩ concentration (17, 44) . In most other smooth muscle types, Ca 2ϩ binds to calmodulin to form an active Ca 2ϩ /calmodulin complex, which activates myosin light chain (MLC) kinase. MLC kinase, in turn, phosphorylates the 20-kDa MLC (MLC 20 ) on Ser 19 , which stimulates myosin ATPase activity and actinmyosin interactions, to induce contraction. MLC 20 phosphorylation is reversed by MLC phosphatase (MLCP). Agonistinduced contractions of vascular smooth muscle are associated with a higher force-to-Ca 2ϩ ratio compared with depolarization-induced contractions, which suggests that a portion of the agonist-induced contraction of smooth muscle is due to increased sensitivity of the contractile apparatus to Ca 2ϩ (5, 28) . Two important signaling pathways involved in modulating the Ca 2ϩ sensitivity of the smooth muscle contractile apparatus in response to agonist stimulation are Rho-associated kinase (ROCK) and PKC (43) .
PKC is activated by agonists that stimulate phosphoinositol turnover and plays a critical role in the regulation of smooth muscle contraction and modulation of the Ca 2ϩ sensitivity of the contractile apparatus (25, 33, 48) . Activation of PKC with phorbol ester results in Ca 2ϩ -independent contraction of smooth muscle (22) , which may be due to the inhibition of MLCP (25) . PKC-dependent inhibition of MLCP and Ca 2ϩ sensitization occurs via phosphorylation of the 17-kDa PKCpotentiated phosphatase inhibitor protein [17-kDa C-kinasepotentiated protein phosphatase-1 inhibitor (CPI-17)]. CPI-17 is a smooth muscle-specific protein that potently inhibits MLCP activity upon phosphorylation at Thr 38 (12) . We (10) have previously reported that permeabilization of lymphatic muscle with ␤-escin is associated with reduced Ca 2ϩ sensitivity and loss of ϳ50% of endogenous CPI-17 compared with permeabilization with ␣-toxin. In addition, we (29, 49) have shown that inhibition of MLC 20 phosphorylation significantly decreased tonic force generation of lymphatics without significantly altering the phasic contraction amplitude. Furthermore, tonic contraction induced by substance P (SP) is decreased by inhibition of MLC 20 phosphorylation (29, 49) . However, there is relatively little information available as to whether PKC signaling contributes to the regulation of lymphatic muscle contraction. In fact, the only publication of the effects of PKC signaling on the lymphatic pump indicated that activation of PKC with phorbol ester inhibited lymph pump activity (36) . Therefore, the objective of this investigation was to determine whether the activation of PKC contributes to the regulation of lymphatic muscle contraction via modulation of myofilament Ca 2ϩ sensitivity. We hypothesized that phorbol ester-induced activation of PKC would enhance the Ca 2ϩ sensitivity of permeabilized lymphatic muscle through MLC 20 phosphorylation-dependent and -independent mechanisms.
MATERIALS AND METHODS

Animals and procedures.
Male Sprague-Dawley rats (250 -400 g) were anesthetized with a combination of diazepam (2.5 mg/kg body wt) and droperidol-fentanyl (0.3 mg/kg). Both drugs were administered via intramuscular injection. A midline abdominal incision was made through the skin, fascia, and abdominal muscle, and a 6-to 7-cm loop of the small intestine was exteriorized. The small intestine and associated mesentery were laid flat on a custom-designed dissection board and superfused with PBS. To isolate cervical lymphatics, the skin was removed from the entire ventral surface of the rat's neck. Underlying fascia layers and superficial muscles were dissected in the area near the external jugular veins. Cervical lymphatics were identified as the comparatively large lymphatic trunk that lays partially on the surface of and partially underneath the external jugular vein. To isolate the thoracic duct (ThD), a midline incision was made through the ventral chest wall. The lungs and heart were carefully moved to the left side of the thoracic cavity to expose the ThD between the aorta and vertebral column.
Segments of lymphatics ϳ1 cm long were isolated, and the vessels were cleared of all surrounding tissues, with care taken to avoid grabbing or pinching them. A segment of lymphatic vessels was then removed and transferred to a 35-mm petri dish containing PSS. After the tissue was removed (in experiments with mesenteric and cervical vessels), the animal was then euthanized by cervical dislocation. All procedures were approved by the Texas A&M University Laboratory Animal Care Committee and adhered to both institutional and federal guidelines.
Isolated vessel procedures. Two stainless steel wires (2 cm long and 25-or 40-m diameter) were passed through the lumen of a 2-mm-long segment of the isolated lymphatic vessel until the vessel was centered along the length of the wires. The wires and lymphatic vessel were transferred to the bath chamber of a single vessel wire myograph (model 310A, Danish Myo Technology, Aarhus, Denmark) containing physiological salt solution (PSS) of the following composition (in mM): 145.0 NaCl, 4.7 KCl, 2.0 CaCl2, 1.17 MgSO4, 1.2 NaH2PO4, 5.0 glucose, 2.0 sodium pyruvate, 0.02 EDTA, and 3.0 MOPS. The two wires were then secured to the mounting jaws of the myograph. One jaw was under control of a manual micropositioner, which was used to adjust the distance between the wires and, therefore, the amount of stretch placed on the vessel. The other jaw was coupled to a force transducer, which was regularly calibrated according to the manufacturer's instructions (Danish Myo Technology). The force output was digitized with a PCI-6030e analog-to-digital card and interface (National Instruments, Austin, TX). Experiments were recorded using a custom LabView (National Instruments) program at a sampling frequency of 10 Hz and stored on a PC (Dell, Austin, TX). Once the wires were secured to the mounting jaws, the myograph was transferred to the stage of an inverted microscope (Olympus CKX41, Leeds Instruments, Irving, TX), which was coupled to a chargecoupled device camera (model PK-M2U, Hitachi Denshi, Woodbury, NY). The vessel was displayed on a television monitor, and a video micrometer (Microcirculation Research Institute, Texas A&M University, College Station, TX) was used to measure the distance between the wires.
Experimental protocols on intact lymphatics. All experiments were performed at 25°C. The lymphatic segment was allowed to equilibrate for ϳ30 min in PSS before the experiments began. After equilibration in an unloaded state (i.e., mounting wires together), the mounting wires were separated, and the preload was increased in 0.05-mN increments until it reached 0.30 mN, which we found to be the optimal preload for these vessels (10, 53, 54) . Each step was 2 min in length to account for the stretch relaxation observed in these vessels (8) . For lymphatics exhibiting spontaneous phasic contractions, the force during diastole was used as preload. Once the preload was set to 0.30 mN, the lymphatic was maximally activated with PSS with an equimolar substitution of KCl for NaCl (KPSS) supplemented with 1 M SP (KPSS ϩ SP) for 5 min. After maximal activation, the lymphatic vessel was bathed in PSS for 5 min to allow the vessel to relax. This procedure of activation/relaxation was repeated until the contractile response to KPSS ϩ SP had stabilized.
Permeabilization and solutions. After the maximal contractile response of the intact lymphatic was determined, the bathing solution was rapidly changed from PSS to high relaxing (HR) solution of the following composition (in mM): 53.3 KCl, 6.81 MgCl 2, 0.025 CaCl2, 10 EGTA, 5.4 Na2ATP, and 12 creatine phosphate. The lymphatic was allowed to incubate in HR solution for 5-10 min. The lymphatic was then permeabilized with 500, 1,000, or 1,500 U/ml (for mesenteric, cervical, or ThD samples, respectively) ␣-toxin from Staphylococcus aureus (Calbiochem) in pCa 6.5 solution. The permeabilization was determined to be complete when the contraction elicited by pCa 6.5 solution reached a plateau, which generally occurred in 30 -45 min. After permeabilization, the lymphatic was incubated with 10 M A-23187 in HR solution for 20 min to deplete intracellular Ca 2ϩ stores (23) . HR solution was then exchanged three to four times to ensure that ␣-toxin and A-23187 had been completely removed. The compositions of the solutions used in these protocols have been previously described (10) .
Experimental protocols on permeabilized lymphatics. The myograph force was rezeroed after the permeabilization procedures. The lymphatic was maximally activated with pCa 4.5 solution for 5 min to determine whether the permeabilization was successful. In general, the maximal contractile force of a lymphatic after permeabilization was 150 -200% of the maximal contractile force of the intact lymphatic elicited by KPSS ϩ SP (data not shown). The bathing solution was rapidly exchanged with HR solution, and the lymphatic was allowed to relax.
We determined whether the stimulation of PKC signaling with phorbol ester had a significant effect on the Ca 2ϩ sensitivity of the lymphatic myofilament at a physiologically relevant Ca 2ϩ concentration. In intact lymphatics, the peak Ca 2ϩ concentration associated with phasic contractions was ϳ300 nM (e.g., in pCa 6.5 solution) (52) . Permeabilized lymphatics were contracted with pCa 6.5 solution, and phorbol ester [either 1 M PMA or phorbol dibutyrate (PDBu)] was then added once a steady-state level of force had developed. The addition of phorbol ester resulted in strong, slowly developing tonic contractions. The lymphatic was maximally activated with pCa 4.5 solution once a steady-state response to the phorbol ester was reached (ϳ15-30 min).
We determined the pCa-force relationship in ␣-toxin-permeabilized lymphatics in the absence or presence of either PMA or PDBu (1 M) to determine whether PKC activation affected the Ca 2ϩ sensitivity of the lymphatic contractile apparatus. After the initial contrac-tion with pCa 4.5 solution, the lymphatic was allowed to relax in HR solution. Once the baseline force had stabilized, the pCa-force relationship was determined by bathing the permeabilized lymphatic in solutions of sequentially increasing Ca 2ϩ concentrations ranging from pCa 8.0 to 4.5, and force was recorded for 3-5 min in each of the pCa solutions. As indicated, some lymphatics were preincubated with 1 M PMA or PDBu in HR solution for 20 -30 min before the pCa-force relationship was determined, and the same phorbol ester concentration was maintained in all of the contracting solutions. We did not detect any effect of either PMA or PDBu on contractile force during the incubation with HR solution (data not shown).
Contraction and relaxation kinetic analysis. We determined whether PKC activation affected the rates of force development and relaxation in ␣-toxin-permeabilized lymphatic muscle. To determine the effect of PKC activation on the rate of force production, lymphatic muscle was activated with pCa 6.5 solution in the absence or presence of phorbol esters, and force was recorded. Raw force data were fit with a sigmoidal curve and then smoothed using a 25-point rolling average. The first derivative of force data was calculated and smoothed (using a moving average of window size 11). The peak derivative (change in force/change in time) was determined to represent the maximal rate of force development (in mN/s) in response to pCa 6.5 solution.
To determine the effect of PKC activation on the rate of relaxation, permeabilized lymphatic muscle was maximally activated with pCa 4.5 solution either before or after addition of phorbol ester. After maximal activation with pCa 4.5 solution, the bathing solution was rapidly exchanged with HR solution, and force was recorded. The force during relaxation was normalized to the maximum force at the beginning of the relaxation period. Normalized data were fit with a monoexponential decay equation, and the time for the vessel to relax by 50% (T 1/2 relaxation) was determined.
Western blot analysis. Mesenteric lymphatic vessels were isolated and permeabilized as described above. After permeabilization, the lymphatics were incubated in one of the following solutions: HR solution (10 min), pCa 6.5 solution (10 min), or pCa 6.5 ϩ PMA (1 M) solution (30 min). The lymphatics were quickly frozen with liquid nitrogen at the time points indicated. The lymphatics were then resuspended in a protein-solubilizing solution and repeatedly exposed to freezing and sonicating conditions to isolate protein. Samples were then run on a 4 -18% SDS-polyacrylamide gradient gel and transferred to a nitrocellulose membrane using a Bio-Rad transblot apparatus. The transfer was verified with Ponceau-S staining. CPI-17 and caldesmon proteins were detected with specific antibodies [Epitomics, Burlingame, CA (1:1,000 dilution), and Cell Signaling Technology, Beverly, MA (1:1,000 dilution), respectively]. Phosphorylated (p-) CPI-17 Thr 38 and p-caldesmon Ser 789 were detected using phosphospecific antibodies [MBL, Woburn, MA (1:1,000 dilution), and Upstate, Bellerica, MA (1:1,000 dilution), respectively]. Antibody binding was revealed using the Pierce detection system (SuperSignal West Dura Extended Duration Substrate, Pierce, Rockford, IL). Densitometry of the resulting bands was performed using the basic Quantity One program (Bio-Rad, Hercules, CA). Densitometric ratios of p-CPI-17 to CPI-17 and p-caldesmon to caldesmon were used to detect changes in phosphorylation of these proteins under the different conditions. Western blot analysis of proteins followed by quantification was performed three times for each sample, and the resulting mean Ϯ SE values were calculated.
Measurements of MLC20 phosphorylation by urea glycerol gel electrophoresis. MLC20 phosphorylation in the rat ThD was analyzed by urea glycerol gel electrophoresis as previously described with a few modifications (29, 38, 47) . Briefly, lymphatic vessels were isolated, treated with PDBu (1 M) for 3 or 10 min, and snap frozen in liquid nitrogen. Vessels were then rapidly immersed in a solution of 10% trichloroacetic acid, acetone, and 10 mM DTT and frozen in a slurry of dry ice and acetone for 10 min. Vessels were then removed from the dry ice and allowed to warm to room temperature in the acetone-trichloroacetic acid solution for 1 h. Tissues were then washed twice with acetone containing 10 mM DTT and minced into small pieces. Tissue pieces were then placed in urea glycerol gel buffer containing 8 M urea and sonicated by a hand-held sonicator. Samples were electrophoresed in glycerol polyacrylamide gels at 400 V, and proteins were then transferred to a nitrocellulose membrane overnight. Mono-, di-, and nonphosphorylated forms of MLC 20 were detected by Western blot analysis using polyclonal MLC 20 antibody (Sigma, 1:5,000 dilution). The migration rate of the monophosphorylated form of MLC 20 was faster than nonphosphorylated MLC 20, and, hence, two bands were detected on the blot. Quantity One software (Bio-Rad) was used to quantify the intensities of the two MLC 20 bands obtained on the blots. The percentage of monophosphorylation of MLC 20 levels from the urea glycerol gels was calculated using the following formula: (monophosphorylated MLC 20/monophosphorylated MLC20 ϩ nonphosphorylated MLC 20) ϫ 100.
Immunohistochemistry. Lymphatic vessels were isolated and permeabilized as described above and then incubated under one of the following conditions: 1) HR solution for 10 min (control), 2) pCa 6.5 solution for 10 min, or 3) pCa 6.5 ϩ 1 M PDBu solution for 10 min. Vessels were fixed in 2% paraformaldehyde-PBS for 60 min at room temperature. After fixation, the lymphatics were washed three times with PBS. The lymphatics were then permeabilized with Ϫ20°C methanol for 5 min and washed with PBS three more times for 5 min each. Vessels were then cut in half with one end being used for the experimental treatment and the other end serving as the negative control. Vessels were incubated with mouse anti-p-MLC 20 monoclonal antibody (Cell Signaling Technology, 1:100 dilution in 1% BSA and 5% normal goat serum in PBS) overnight. Vessels were washed with PBS three times for 5 min and then incubated with goat anti-mouse secondary antibody conjugated to Oregon green 488 (Molecular Probes, Carlsbad, CA) for 60 min at room temperature. Vessels were washed three times for 5 min each with PBS and placed on the stage of a confocal microscope (Leica TCS SP2) for observations with a ϫ20 Nikon objective. Vessels were scanned in 0.5-m z-axis steps, and reconstructions of the three-dimensional (3-D) image stacks were performed using the Leica Confocal software package to produce flat average projections. Negative control vessel segments were subjected to the same procedures as the experimental treatments except that the negative controls were incubated with normal mouse IgG instead of the primary antibody. Negative controls were scanned at the same microscope settings as the experimental treatments to allow for valid comparison of the relative fluorescent intensities.
The fluorescence intensity of the p-MLC20 signal was quantified using the integrated 3-D projections of the 3-D image stacks. Each 3-D data set included two segments of the same lymphatic vessel; one segment was from an experimental treatment and the other its corresponding IgG negative control. Mean fluorescence intensities were determined in the lymphatic segments using thresholding techniques to outline the segments. In general, two to four sets of 3-D projections were produced from a single vessel. These data sets were averaged so that each vessel represented a single experiment. The integrated intensities, which represented p-MLC20 in each vessel, were determined for each treatment (i.e., HR solution, pCa 6.5 solution, and pCa 6.5 ϩ PDBu solution) for each experiment. Since we determined p-MLC20 levels at pCa 6.5 solution in each experiment, data were normalized to the pCa 6.5 treatment value for each experiment and are presented as a ratio of the p-MLC20 signal intensity in the experimental treatments relative to their pCa 6.5 solution treatment.
Statistical analysis. Data are presented as means Ϯ SE. Tension (in mN/mm) was calculated by dividing force by two times the length of the lymphatic segment (in mm). The pCa-tension relationship was normalized to the response at pCa 4.5 solution and fit to the Hill equation using Prism software, as previously described (10) . A Student's paired t-test was used to determine differences between the tension developed at pCa 6.5 solution in the absence or presence of phorbol ester (Figs. 1 and 2 ) and T 1/2 relaxation (Fig. 3 ). An independent sample t-test was used to determine differences between pCa50 and the Hill coefficient in the absence or presence of phorbol ester (Fig. 2) . ANOVA was used to determine differences in band intensity between treatments after Western blot analysis (Figs. 5 and 7) and immunohistochemistry (Fig. 6 ). Tukey's post hoc analysis was performed to determine between group differences. Significance was set at P Ͻ 0.05.
RESULTS
The addition of 1 M PDBu (Fig. 1A) or 1 M PMA (Fig.  1B) to ␣-toxin-permeabilized mesenteric lymphatic muscle submaximally activated with pCa 6.5 solution elicited very powerful, slowly developing, and sustained contractions (15-30 min) . The steady-state tension produced in permeabilized lymphatic muscle at pCa 6.5 solution was significantly increased in the presence of phorbol ester (PDBu: 0.02 Ϯ 0.01 vs. 0.63 Ϯ 0.05 mN/mm and PMA: 0.06 Ϯ 0.01 vs. 0.63 Ϯ 0.05 mN/mm, n ϭ 5; Fig. 2, A and C) . The phorbol esterinduced contraction of submaximally activated permeabilized lymphatics significantly increased the steady-state tension from ϳ5-10% to Ͼ90% of the maximum contraction elicited at pCa 4.5 solution (Fig. 2, A and C) . Thus, phorbol ester-dependent activation of PKC induces a significant increase in steady-state tension independent of an increase in Ca 2ϩ levels in ␣-toxinpermeabilized lymphatic muscle exposed to submaximal Ca 2ϩ activation.
We determined whether PKC activation affects the pCatension relationship in permeabilized lymphatic muscle. As shown in Fig. 2, B and D, the pCa-tension relationship was significantly shifted to the left in the presence of 1 M PMA or PDBu. The pCa 50 (32) .
Data were analyzed further to determine whether activation of PKC modulated the rate of contractile force generation. The maximal rate of force development in response to pCa 6.5 solution was significantly increased when permeabilized lymphatic rings were preincubated with phorbol ester (0.047 Ϯ 0.011 mN/s in control vs. 0.081 Ϯ 0.007 mN/s in phorbol ester, n ϭ 5, P Ͻ 0.05). There was no significant difference between the maximal rate of force development in the presence of either PDBu or PMA (0.07 Ϯ 0.00 mN/s in PDBu vs. 0.09 Ϯ 0.01 mN/s in PMA, n ϭ 5, P ϭ 0.11), so these data were combined. These data suggest that PKC-dependent activation of the lymphatic myofilament increases the rate of contraction in response to a Ca 2ϩ signal. As shown in Fig. 3 , we determined the effect of PKC activation on the rate of relaxation in ␣-toxinpermeabilized lymphatic muscle after maximal activation with pCa 4.5 solution. The T 1/2 relaxation was significantly increased after the activation of PKC (0.28 Ϯ 0.02 min in control vs. 1.60 Ϯ 0.13 min in phorbol ester, n ϭ 5, P Ͻ 0.05). Taken together, these data indicate that PKC-dependent activation of permeabilized lymphatic muscle simultaneously accelerates the rate of contraction and decelerates the rate of relaxation.
To assess whether the effects of phorbol ester were specific to mesenteric collecting lymphatics, we investigated how phorbol ester would influence the tension development in large transport lymphatics, i.e., cervical lymphatic vessels (CLV) and ThD. As shown in Fig. 4 , the steady-state tension produced by permeabilized CLV and ThD lymphatic muscle at pCa 6.5 solution was significantly increased in the presence of PDBu (CLV: 0.05 Ϯ 0.01 vs. 0.73 Ϯ 0.05 mN/mm, n ϭ 5, P Ͻ 0.05; ThD: 0.06 Ϯ 0.01 vs. 0.74 Ϯ 0.04 mN/mm, n ϭ 5, P Ͻ 0.05). The phorbol ester-induced contraction of submaximally activated permeabilized lymphatics significantly increased the steady-state tension from ϳ5-10% to Ͼ90% of the maximum contraction elicited in pCa 4.5 solution (Fig. 4) .
The regulation of smooth muscle contraction is primarily due to the phosphorylation of residue Ser 19 on MLC 20 (43) . Our data indicate that the addition of phorbol ester to submaximally activated (i.e., pCa 6.5 solution) permeabilized lymphatic muscle results in an ϳ10-to 30-fold increase in steadystate force production. We hypothesized that the Ca 2ϩ -sensitizing effects of phorbol ester would be due to an increase in Ser 19 phosphorylation on MLC 20 . To ascertain differences in the levels of MLC 20 phosphorylation after PDBu treatment, we quantified MLC 20 phosphorylation at two different time points (3 and 10 min) after PDBu treatement. As shown in Fig. 1A , tension development by lymphatic muscle increases sharply within the first 3 min after PDBu treatment and then continues to slowly increase to a plateau level of tension. We quantified MLC 20 phosphorylation using urea glycerol gel electrophoresis of proteins isolated from ThDs treated with PDBu for 3 or 10 min. We did not perform this analysis in mesenteric lymphatics since the available biomass is limited from the mesentery; however, we performed immunofluorescence in mesenteric vessels (see Fig. 6 ). As shown in Fig. 5A , a second band corresponding to monophosphorylated MLC 20 was found in ThDs treated with PDBu for 3 min. As shown in Fig. 5 , monophosphorylated MLC 20 levels were significantly increased in vessels treated with PDBu for 3 min (38.88 Ϯ 0.86% vs. 2.24 Ϯ 0.62%, n ϭ 4, P Ͻ 0.05) compared with the untreated ThD, whereas vessels treated with PDBu for 10 min showed no significant changes in relative levels of monophosphorylated MLC 20 (2.40 Ϯ 0.89% vs. 2.95 Ϯ 1.45%, n ϭ 4) compared with values for control vessels.
We also performed immunofluorescence experiments on ␣-toxin-permeabilized mesenteric lymphatic muscle to further determine whether increased MLC 20 phosphorylation could be detected in vessels incubated for 10 min with pCa 6.5 solution containing 1 M PDBu (pCa 6.5 ϩ PDBu) compared with those incubated in pCa 6.5 solution alone or HR solution (Fig. 6) . Since the immunofluorescence approach in a cannulated vessel is technically challenging to conduct at shorter time points due to the necessity of removing the vessel from the cannulation pipettes and immediate freezing it, we performed this experiment only for vessels treated with PDBu for 10 min. Incubation Fig. 2 . Summary of the contractile response of ␣-toxin-permeabilized mesenteric lymphatic muscle to activation by pCa 6.5 solution in the absence or presence of phorbol ester. The addition of either PDBu (A) or PMA (C) significantly increased the steadystate tension of permeabilized lymphatic muscle that was submaximally activated by pCa 6.5 solution. The steady-state response was normalized to the maximal response in pCa 4.5 solution. The pCa-tension relationship was determined in ␣-toxin-permeabilized lymphatic muscle in the absence or presence of the phorbol esters PDBu (B) or PMA (D). The steady-state force response to the indicated Ca 2ϩ concentrations were plotted and fit to the Hill equation. n ϭ 5. *P Ͻ 0.05. Fig. 3 . Representative tracings of the relaxation of ␣-toxin-permeabilized lymphatic muscle after maximal activation with pCa 4.5 solution before or after the activation of PKC with phorbol ester. Force data were normalized to the force at the beginning of the relaxation period. Data were fit to a monoexponential decay equation, and the time to reach 50% relaxation (T1/2 relaxation) was calculated. The activation of PKC with phorbol ester (n ϭ 6) significantly increased T1/2 relaxation compared with control (n ϭ 6).
of ␣-toxin-permeabilized lymphatics with pCa 6.5 solution (Fig. 6B) or pCa 6.5 ϩ PDBu solution (Fig. 6C ) was associated with a significant increase in the detected pMLC 20 fluorescence intensity compared with HR solution (Fig. 6A) . However, we did not detect any significant difference in MLC 20 phosphorylation when permeabilized lymphatic muscle was incubated in pCa6.5 ϩ PDBu solution for 10 min compared with pCa 6.5 solution alone (Fig. 6D ).
An important mechanism underlying the PKC-dependent Ca 2ϩ sensitization of vascular smooth muscle involves the phosphorylation of CPI-17 at Thr 38 , which activates CPI-17 to inhibit MLCP and cause contraction. Using a phospho-specific antibody that recognizes p-CPI-17, we performed Western blot analysis to determine whether the sustained phorbol esterinduced contraction and Ca 2ϩ sensitization was associated with increased CPI-17 phosphorylation at Thr 38 in permeabilized lymphatic muscle. As shown in Fig. 7A , we detected a low level of CPI-17 phosphorylation at Thr 38 in unstimulated lymphatics (HR solution). Activation of ␣-toxin-permeabilized lymphatics in pCa 6.5 ϩ PMA solution did not statistically alter CPI-17 phosphorylation compared with the level in pCa 6.5 solution alone.
Phosphorylation of caldesmon has been postulated as an important regulatory mechanism of smooth muscle contraction (17) . We performed Western blot experiments using a phospho-specific antibody that recognizes the phosphorylated Ser 789 site on caldesmon. As shown in Fig. 7B , caldesmon was phosphorylated at Ser 789 in permeabilized lymphatic muscle incubated with HR solution. However, incubation with pCa 6.5 solution or pCa 6.5 ϩ PMA solution did not significantly increase the phosphorylation of caldesmon at Ser 789 .
DISCUSSION
The results presented here represent the first demonstration of the contribution of PKC signaling to the regulation of lymphatic muscle contraction. Our data indicate that the activation of PKC with phorbol ester induces a significant increase in the contractile force of submaximally activated ␣-toxinpermeabilized lymphatic muscle independent of a change in intracellular Ca 2ϩ concentration. Moreover, we report that the pCa-tension relationship of ␣-toxin-permeabilized lymphatic muscle is significantly shifted to the left in the presence of phorbol ester, indicating enhanced Ca 2ϩ sensitivity of the contractile apparatus. Our Western blot and immunohistochemistry data indicate that the initial rapid increase in tension development after stimulation by PDBu is associated with MLC 20 phosphorylation; however, the later, steady-state Ca ThDs were equilibrated at pCa 6.5 and were either treated with PDBu for 3 min (3=) or 10 min (10=) or left untreated. Protein samples were isolated and separated by urea glycerol gel electrophoresis, as described in MATERIALS AND METHODS. A: representative blot showing the separation of the two forms of MLC20, the unphosphorylated form of MLC20 (MLC) and the monophosphorylated form of MLC20 (MLC-P), in untreated and PDBu-treated vessels, respectively. B: graphical representation of the densitometry analysis of the individual mono-and nonphosphorylated bands of MLC20 in both control and PDBu-treated samples. Results are expressed as a percentage of the total MLC20 phosphorylation detected in the blots. Experiments were repeated four times, and the means Ϯ SE were calculated and plotted. n ϭ 4. *P Յ 0.05.
at Thr 38 , or caldesmon at Ser 789 . The activation of PKC by phorbol esters increased the maximal rate of force development in response to pCa 6.5 solution, whereas the rate of relaxation in HR solution after maximal activation with pCa 4.5 solution was reduced. Collectively, these data suggest that the activation of PKC signaling is an important Ca 2ϩ -sensitizing mechanism in lymphatic muscle that involves potentially novel mechanisms.
Lymphatic muscle contractile activity is modulated by various neurohumoral and physical factors, which are known to enhance the Ca 2ϩ sensitivity of the vascular smooth muscle contractile apparatus (11, 28) . For example, Benoit and colleagues (2) reported that activation of ␣-adrenergic receptors with PE resulted in enhanced tonic and phasic contractile activity in rat mesenteric lymphatics. Similarly, stimulation of guinea pig lymphatics with histamine increases pump activity (14) . Interestingly, Shirasawa and Benoit (39) reported that the strength of phasic contractions of the rat ThD was enhanced with stretch and was independent of an increase in the Ca 2ϩ transient. These authors concluded that the stretch-enhanced pumping was due to Ca 2ϩ sensitization of the lymphatic contractile apparatus. We (49) have shown that an increase in intramural pressure decreases the tone of lymphatic muscle, which correlates with a decrease in MLC 20 phosphorylation. However, there is little direct evidence as to whether enhanced Ca 2ϩ sensitivity of the contractile apparatus contributes to agonist-induced stimulation of lymphatic pump activity. Also, the signaling mechanisms that modulate the Ca 2ϩ sensitivity of the lymphatic contractile apparatus remain to be established.
The activation of PKC and ROCK are the primary signaling mechanisms involved in vascular smooth muscle Ca 2ϩ sensitization (43); however, there is a paucity of data related to their roles in lymphatic muscle. Hosaka and colleagues (19) reported that inhibition of ROCK signaling with Y-27632 in intact rat collecting lymphatics abolishes tone and pump activity. In addition, Y-27632 inhibited tonic contractions elicited by norepinephrine, U-46619, and KCl, suggesting an important role for ROCK in mediating the agonist-induced changes in lymphatic muscle contraction (18) . Furthermore, it has been shown that RhoA/ROCK-mediated Ca 2ϩ sensitivity plays an essential role in alcohol-induced inhibition of lymphatic myogenic constriction (46) . In intact bovine lymphatics, Rodela and coworkers (36) reported that the phorbol ester-dependent activation of PKC inhibited lymphatic pump activity via endothelium-dependent mechanisms. In contrast, we found that the activation of PKC with phorbol esters, PMA or PDBu, results in a potent contraction and Ca 2ϩ sensitization of permeabilized lymphatic muscle. Thus, our data are the first to suggest that an important role of PKC activation in lymphatic muscle is to modulate contraction via enhancement of myofilament Ca 2ϩ sensitivity. Recently, we (10) reported that the loss of CPI-17 from ␤-escin-permeabilized lymphatic muscle was associated with lower Ca 2ϩ sensitivity compared with lymphatics permeabilized with ␣-toxin. PKC-dependent Ca 2ϩ sensitization of smooth muscle is associated with phosphorylation of CPI-17 at Thr 38 , which inhibits MLCP and results in increased MLC 20 phosphorylation at Ser 19 (24) . Therefore, we hypothesized that phorbol ester-induced Ca 2ϩ sensitization of lymphatic muscle would be associated with increased phosphorylation of CPI-17 and MLC 20 . However, there was no significant effect of PMA on CPI-17 phosphorylation. We also did not detect a significant increase in the phosphorylation of MLC 20 in ␣-toxin-permeabilized lymphatic muscle incubated with phorbol ester under steady-state conditions 10 min after activation that elicited ϳ90% of the maximal contraction (Figs. 5 and 6) , although there was a rise in the phosphorylation of MLC 20 in the early phase (3 min after activation) of the contraction (Fig. 5) . Thus, our data indicate that the steady-state PKC-dependent Ca 2ϩ sensitization of permeabilized lymphatic muscle is not associated with increased CPI-17 and MLC 20 phosphorylation. Although our results do not suggest a role for CPI-17-dependent signaling in the sustained Ca 2ϩ sensitization of permeabilized lymphatic muscle to phorbol ester, it remains to be determined whether CPI-17 is activated at an earlier time point than we observed in response to PKC stimulation and whether CPI-17 signaling is a critical Ca 2ϩ -sensitizing mechanism downstream of ROCK (31) and integrin-linked kinase (20) .
Phosphorylation of caldesmon reverses its affinity for actin and, therefore, relieves its inhibition of actin-activated myosin ATPase activity (30) . Although caldesmon is phosphorylated on a number of sites in vitro, the majority of phosphate incorporation in vivo occurs at the Ser 759 and Ser 789 sites of the mammalian sequence, which are the primary sites phosphorylated in response to PKC activation (7) . Phosphorylation at Ser 789 is the primary site phosphorylated at rest and in response to agonist stimulation (7) . Therefore, we tested whether phorbol ester-induced Ca 2ϩ sensitization of permeabilized lymphatic muscle was associated with an increase in the phosphorylation of caldesmon at Ser 789 . We did not detect a significant increase in caldesmon phosphorylation at Ser 789 (Fig. 7) . Similar to the report by D'Angelo and colleagues (7), we found that Ser 789 of caldesmon was phosphorylated in unstimulated lymphatic muscle and that this phosphorylation was not significantly changed by phorbol ester treatment. Thus, the steady-state contraction of permeabilized lymphatic muscle elicited by phorbol ester is not associated with increased phosphorylation of caldesmon at Ser 789 . The level of Ser 759 phosphorylation was not determined as part of this investigation, so it cannot be ruled out that PKC-dependent phosphorylation of caldesmon at Ser 759 contributes to the phorbol ester-induced contraction and Ca 2ϩ sensitization of permeabilized lymphatic muscle.
Our finding that phorbol ester-induced contraction of permeabilized lymphatic muscle is not associated with a sustained increase in MLC 20 phosphorylation is not without precedent. For example, Chatterjee and Tejada (6) reported that phorbol ester-induced contraction of Triton X-100 skinned vascular smooth muscle was not associated with a significant change in MLC 20 phosphorylation, although significant increases in the phosphorylation of MLC 20 were observed in response to agonist or depolarizing stimuli. Likewise, Jiang and Morgan (21) reported that phorbol ester-induced contraction of the intact ferret aorta was not associated with a significant increase in MLC 20 phosphorylation. There are several potential thin filament regulatory mechanisms that may contribute to the PKCdependent Ca 2ϩ sensitization of permeabilized lymphatic muscle that were not tested in the present investigation. Calponin, like caldesmon, is an actin-associated protein found in smooth muscle that inhibits actin-activated myosin ATPase activity (50, 51) . PKC-dependent phosphorylation of calponin reverses its inhibition of smooth muscle contraction in vitro (51) , and increased phosphorylation of calponin has been reported in stimulated canine tracheal smooth muscle (16) and ferret aorta smooth muscle (48) . Another potential mechanism involves PKC-dependent phosphorylation of 27-kDa heat shock protein (HSP27). Bitar et al. (4) reported that the sustained contraction of colonic smooth muscle in response to bombesin and phorbol ester was due to the phosphorylation of HSP27. Subsequently, it has been previously reported that PKC-dependent contraction of colonic smooth muscle is associated with the phosphorylation of HSP27, which modulates its interaction with various myofilament proteins, including tropomyosin (42) and caldesmon (41) , to promote contraction. Thus, PKC-dependent phosphorylation of calponin or HSP27 may be critical in the regulation of lymphatic muscle contraction, which warrants further examination. Sustained activation of PKC altered the contraction and relaxation kinetics in permeabilized lymphatic muscle. Phorbol ester-induced activation of PKC accelerated the rate of force development in response to pCa 6.5 solution. These data are consistent with a previous report (35) showing that activation of PKC accelerated the contraction kinetics in airway smooth muscle. Assuming that MLC 20 phosphorylation is the ratelimiting step in the rate of force development by vertebrate smooth muscle (45) and that PKC does not directly phosphorylate MLC 20 on Ser 19 (40) , then our analysis of the contraction kinetics data is consistent with the hypothesis that PKC inhibits MLCP activity in lymphatic muscle. Sustained activation of PKC was also associated with a reduced rate of relaxation after maximal activation of permeabilized lymphatic muscle with pCa 4.5 solution. These data are similar to those reported by Masuo and colleagues (25) in permeabilized vascular smooth muscle. As discussed below, dissociation of contractile force and MLC 20 phosphorylation after the sustained activation of PKC may be due to enhanced cooperativity between phosphorylated and unphosphorylated cross-bridges, i.e., the sustained contraction and slowed rate of relaxation may reflect attachment and force production by strongly bound, unphosphorylated myosin cross-bridges. Interestingly, Fitzsimons and coworkers (13) reported that strongly bound, nonforce generating myosin cross-bridges slowed the relaxation kinetics in skinned cardiac muscle. Thus, our data suggest that the activation of PKC in lymphatic muscle may facilitate the formation of strongly bound cross-bridges that may contribute to the altered contraction and relaxation kinetics observed in the present study. The attachment of unphosphorylated myosin crossbridges to actin is generally referred to as the latch state, due to the slow cross-bridge cycling rate, and is considered to be an important mechanism in the ability of smooth muscle to maintain tonic contraction at a low metabolic cost (9) . Thus, we propose that phorbol ester stimulation of permeabilized lymphatic muscle induces a robust increase in MLC 20 phosphorylation in the earlier phase that facilitates cooperative activation and attachment of unphosphorylated cross-bridges, which contribute to the slow sustained contraction observed in the later steady state. Our data indicate that phorbol ester-induced tension development is associated with a transient increase in MLC 20 phosphorylation; however, the sustained contraction of ␣-toxin-permeabilized lymphatic muscle is not associated with increased phosphorylation of MLC 20 , CPI-17, or caldesmon.
In summary, we report here, for the first time, that the activation of PKC signaling with phorbol ester induces strong contractions and increases the Ca 2ϩ sensitivity of the contractile apparatus in ␣-toxin-permeabilized lymphatic muscle. In addition, our data indicate that the sustained PKC-dependent Ca 2ϩ sensitization of permeabilized lymphatic muscle involves MLC 20 phosphorylation-dependent and -independent mechanism(s). Future experiments characterizing the roles of PKC signaling and other Ca 2ϩ -sensitizing mechanisms in modulating lymph pump activity in response to agonist stimulation are warranted. 
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